Corporate News – Cnlight (002076.SZ)

  • Trading Activity (24‑hour period ending 05:39 PM Central Europe, Thursday 22 Oct 2026)

  • Cnlight traded flat, 0 % change.

  • Current price: CNY 2.70.

  • Total shares outstanding: 1 billion.

  • Market capitalization: CNY 2.5 billion.

  • 24‑hour trading volume: CNY 141.3 million.

  • Since the close of the previous month, the share price has risen 13.43 %.

  • 200‑day simple moving average: CNY 2.21.

  • 52‑week high: CNY 2.83 (recorded 29 May 2026).

  • 52‑week low: CNY 1.74 (recorded 21 Jul 2026).

  • Market Context

  • The Chinese stock market recorded a broadly negative sentiment during the trading day.

  • Major indices—Shanghai Composite, Shenzhen Component, and ChiNext Composite—all posted declines.

  • Trading volume across the market contracted modestly compared with the previous session.

  • Despite the overall downturn, data‑related themes (e.g., data‑to‑AI and related software) showed modest gains.

  • Certain names in electrical equipment and consumer goods experienced limited upside.

  • Investors largely focused on defensive and dividend‑heavy positions while awaiting further macroeconomic clarification and corporate disclosures.

  • Recent Performance of Peer Stocks (Last 24 Hours)

    TickerChangeCurrent PriceMarket CapitalizationP/E Ratio
    Gstarsoft (688657.SS)0 %CNY 31.20CNY 3 billion68.38
    Gad (300902.SZ)0 %CNY 15.76CNY 3 billion—
    Tspc (000554.SZ)0 %CNY 6.01CNY 3 billion17.20
    Shanghai Haohai Biological (6826.HK)+0.26 %HKD 15.41HKD 3.5 billion20.59
    Gddp (300808.SZ)0 %CNY 17.61CNY 3 billion—
  • Summary

  • Cnlight remains stable within the context of a broadly negative market environment.

  • The company’s market capitalization and trading volume are consistent with its liquidity profile.

  • Sector‑specific resilience is limited; overall investor sentiment remains cautious.

  • Peer stocks display varied performance, with Gstarsoft showing a high P/E ratio, indicating potential valuation concerns, while Tspc and Shanghai Haohai Biological maintain moderate valuation metrics.